Description

INTRODUCTION

IDRA-21 is a drug derived from the Benzothiadiazine (not to be confused with Benzodiazepine) chemical structure. Other chemicals from that class include other pharmaceutical drugs, mostly diuretics to prevent organ failure. An article from Chemical Wizardry claims that IDRA-21 is related to Aniracetam, another nootropic with similar (but far weaker) Ampakine properties.

As it is a nootropic substance, IDRA-21 has been shown in a clinical setting to improve cognitive ability with little to no adverse effects. However, it is also important to point out that IDRA-21 is still a very new substance to the world, and still currently has more anecdotal evidence for efficacy compared to the amount of available lab research.

BENEFITS

IDRA-21’s primary benefit is a dramatic improvement in learning and memory. It significantly outperformed Aniracetam and is approximately 10-30 times more potent at reversing cognitive deficits caused by Scopolamine and Alprazolam. In addition, IDRA-21 benefits lasts for up to three days after just one dose.

IDRA-21 is also thought to induce long-term potentiation (LTP). LTP is a long-lasting enhancement in how neurons communicate with in the brain. It is vital for improving synaptic plasticity, which strengthens synapses within the brain. As synapses are largely responsible for memories, enhancing their strength and function is vital to improving overall cognition.

IDRA-21 has potential as a powerful promoter of wakefulness and awareness, thanks to its properties as an Ampakine. Activation of the AMPA receptor results in the easing of learning ability by promoting the plasticity of nerve connections, as well as other Glutamate-mediated effects such as improving situational alertness.

SIDE EFFECTS

Following the classic nootropic definition, IDRA-21 has little to no side effects. In fact, besides the intended benefits (wakefulness, increased learning ability, etc) it does not do much else. Anecdotal reports have included slight anxiety and headaches, which could be related to increased Glutamate neurotransmission in those who already have strong AMPA activity and don’t need IDRA-21.

However, it’s best for people who recently had a stroke to avoid this substance, as it could make damage worse according to this research.

RESEARCH DOSAGE

Dosage: as clinical trials and studies have not taken place for human use there is therefore no officially recommended dosage. Based on sample user testimonials, dosage for humans seems to be between 5mg and 25mg, taken orally. Half-life: 24/36 hours. As any other nootropic it is recommended to start at a lower dose and assess response, until the optimal dosage is established.

Disclaimer